To view quote, trade, company profile, news and filing information, please enable javascript on your browser.
Living Cell Technologies Ltd. - LVCLY
OTCQX International / Security Type:
Business Description
Living Cell Technologies Ltd (ASX:LCT) develops live cell-based therapy products to treat life-threatening human diseases. The company's most advanced product treats type 1 diabetes by implanting microencapsulated porcine islet cells. This achieves near-normal blood-glucose levels with healthy living cells injected into patients to replace damaged tissue, without requiring immunosuppresive drugs to prevent rejection.
Officers and Directors
| David Brookes |
Chairman |
| Paul Tan |
CEO |
| Robert Finder |
Dir. |
| Simon O'Loughlin |
Dir. |
| Laurie Hunter |
Dir. |
| David McAuliffe |
Dir. |
| Nicholas Geddes |
Secretary |
| John Cowan |
Finance Manager |
| Bob Elliott |
Medical Director |
| Susanne Clay |
CBO |
Service Providers
Auditor/Accountant
|
Legal Counsel
|
Investor Relation Firm
Rx Communications Group, LLC
445 Park Avenue 10th Floor
New York, NY 10022
|
|
Other Information
| Industry Classification |
2836 - Biological products, except diagnostic |
| Jurisdiction of Incorporation |
,AUS |
| Year of Incorporation |
2003 |
| CIK |
0001398773 |
| Non Exchange Listing |
ASX - Australian Securities Exchange |
| Market Cap |
5.8052511E7 |
| Shares Outstanding |
272547000 |
